Aurinia Pharmaceuticals Inc · NASDAQ:AUPH
Aurinia Pharmaceuticals — Q3 2025 Earnings Presentation
27 slides from Aurinia Pharmaceuticals's earnings presentation, Nov 4, 2025
Slide 1: Third Quarter 2025 Update
® Third Quarter 2025 Update November 4, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable U.S. securities law and forward-looking information within the meaning of applicable Canadian securities law. We caution investors that forward-looking statements are based on management
Slide 3: Third Quarter 2025 Financial Highlights and Recent Business Progress
Third Quarter 2025 Financial Highlights and Recent Business Progress • Third quarter 2025 LUPKYNIS sales experienced continued momentum following last year’s inclusion in American College of Rheumatology Guidelines, growing 27% • LUPKYNIS sales guidance for 2025 raised for second time this year, to
Slide 4: Third Quarter 2025 Financial Update
Third Quarter 2025 Financial Update ®
Slide 5: Results for the Three Months Ended September 30
Results for the Three Months Ended September 30 Three Months Ended September 30 % Change 2025 2024 Total Revenue $73.5 million $67.8 million a 8% Net Product Sales $70.6 million $55.5 million 27% Net Income $31.6 million $14.4 million 119% Diluted Earnings per Share $0.23 $0.10 130% Cash Flows from
Slide 6: Results for the Nine Months Ended September 30
Results for the Nine Months Ended September 30 Nine Months Ended September 30 % Change 2025 2024 Total Revenue $205.9 million $175.3 million a 17% Net Product Sales $197.2 million $158.6 million 24% Net Income $76.4 million $4.3 million 1677% Diluted Earnings per Share $0.55 $0.03 1733% Cash Flows f
Slide 7: Cash Flows and Financial Position
Cash Flows and Financial Position Three Months Ended Nine Months Ended September 30, 2025 September 30, 2025 Beginning Cash, Cash Equivalents, $315.1 million $358.5 million Restricted Cash and Investments Cash Flows from Operating Activities $44.5 million $90.0 million Repurchase of Shares $(8.7) mi
Slide 8: 2025 Financial Guidance Increase
2025 Financial Guidance Increase Initial Guidance Most Recent Guidance Current Guidance a Total Revenue $250 million to $260 million $260 million to $270 million $275 million to $280 million Net Product Sales $240 million to $250 million $250 million to $260 million $265 million to $270 million Net
Slide 9: LUPKYNIS Update
LUPKYNIS Update \¢ Aurinia”
Slide 10: New Analyses Support LUPKYNIS' Robust Clinical Benefit in Lupus Nephritis
New Analyses Support LUPKYNIS’ Robust Clinical Benefit in the Treatment of Patients with Lupus Nephritis • Aurinia is sharing some new analyses of the results of the Phase 3 (AURORA 1 and AURORA 2) and Phase 2 (AURA-LV) studies that formed the basis of the 2021 FDA approval of LUPKYNIS and the 2024
Slide 11: Time to Renal-Related Event or Death
Time to Renal-Related Event or Death a (AURORA 1 Phase 3 Population) 50 Treatment Events (%) HR (95% CI) P-value LUPKYNIS 45 LUPKYNIS 26 (14.6) 0.466 (0.290, 0.747) 0.0012 Placebo 40 Placebo 51 (28.7) - Censored 35 Probability of Event (%) 30 25 20 15 10 5 0 0 13 26 39 52 65 Probability [N at Risk]:
Slide 12: Aritinercept Update
Aritinercept Update \ Aurinia®
Slide 13: Aritinercept Is a Dual BAFF/APRIL Inhibitor
Aritinercept Is a Dual BAFF/APRIL Inhibitor • Aritinercept contains a BCMA-engineered extracellular binding domain optimized for APRIL BAFF superior affinity to BAFF and APRIL (others use TACI-engineered extracellular binding domain) Engineered extracellular domain of BCMA receptor − BCMA has a stro
Slide 14: Role of BAFF and APRIL
Role of BAFF and APRIL • BAFF and APRIL are important cytokines that regulate B cell survival and differentiation, whose targets are expressed on B cells at different stages of B cell development a • Targeting both BAFF and APRIL depletes a broader set of B cells, including plasma cells, than target
Slide 15: Aritinercept Single Ascending Dose (SAD) Study: Design
Aritinercept Single Ascending Dose (SAD) Study: Design Screening (up to 5 weeks), In-Clinic Phase (1 week) and Out-Patient Visits (13 weeks) Dose Level 6 (n=8 Healthy Subjects) Screening 300 mg SC Placebo n=6 n=2 Dose Level 5 (n=8 Healthy Subjects) Screening 225 mg SC Placebo n=6 n=2 Dose Level 4 (n
Slide 16: Aritinercept SAD Study: Safety Summary
Aritinercept SAD Study: Safety Summary • Aritinercept was well tolerated at all dose levels tested • No treatment-related Grade ≥3 adverse events a • No treatment-related serious adverse events (SAEs) a • No discontinuations due to treatment-related adverse events • Adverse events that occurred in m
Slide 17: Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins
Aritinercept SAD Study: Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins in Humans IgA IgM IgG 20% 20% 20% Mean Change from Baseline 0% 0% 0% -20% -20% -20% -40% -40% -40% Mean IgA reductions Mean IgM reductions Mean IgG reductions of up to 48% of up to 55% o
Slide 18: Summary and Next Steps
Summary and Next Steps • Aritinercept was well tolerated at all dose levels tested • Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins supportive of once-monthly dosing • Aurinia plans to initiate clinical studies of aritinercept in two autoimmune diseases by
Slide 19: Q&A
Q&A wr an Aurinia
Slide 20: Appendix 1: Additional Analyses from LUPKYNIS Phase 3 and Phase 2 Clinical Studies
Appendix 1: Additional Analyses from LUPKYNIS Phase 3 and Phase 2 Clinical Studies ®
Slide 21: Time to Renal-Related Event or Death and Additional Renal-Related Events
Time to Renal-Related Event or Death and Additional Renal-Related Events (AURORA 1 and AURORA 2 Phase 3 Populations) AURORA 1 AURORA 1 and AURORA 2 Integrated Week 0-52 Week 0-156 LUPKYNIS LUPKYNIS PBO Hazard Ratio PBO Hazard Ratio 23.7 mg BID 23.7 mg BID N=178 vs. PBO N=178 vs. PBO N=178 N=178 n (%
Slide 22: Time to Renal-Related Event or Death and Additional Renal-Related Events
Time to Renal-Related Event or Death and Additional Renal-Related Events (AURORA 1 Phase 3, AURA-LV Phase 2 and AURORA 2 Phase 3 Populations) AURORA 1 and AURA-LV Integrated AURORA 1, AURA-LV and AURORA 2 Integrated Week 0-52 Week 0-156 LUPKYNIS LUPKYNIS PBO Hazard Ratio PBO Hazard Ratio 23.7 mg BID
Slide 23: Appendix 2: Immunoglobulin Reductions from Aritinercept and Other BAFF/APRIL Inhibitors
Appendix 2: Immunoglobulin Reductions from Aritinercept and Other BAFF/APRIL Inhibitors ®
Slide 24: Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA Reductions in IgA a 20% Mean % Change Drug from Baseline in IgA (Sponsor) at Day 28 a Mean Change from Baseline 0% Aritinercept -48% (Aurinia) Povetacicept -20% -43% (Vertex) Sibeprenlimab -41% (Otsuka) -40% Atacicept -10% (Vera) Telitacicept -
Slide 25: Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM Reductions in IgM a 20% Mean % Change Drug from Baseline in IgM (Sponsor) at Day 28 a Mean Change from Baseline 0% Aritinercept -55% (Aurinia) Povetacicept -20% -52% (Vertex) Sibeprenlimab -39% (Otsuka) -40% Atacicept -17% (Vera) Telitacicept -
Slide 26: Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG Reductions in IgG a 20% Mean % Change Drug from Baseline in IgG (Sponsor) at Day 28 a Mean Change from Baseline 0% Aritinercept -20% (Aurinia) Povetacicept -20% -19% (Vertex) Sibeprenlimab -13% (Otsuka) -40% Atacicept N/A b (Vera) Telitacicept
Slide 27: © Aurinia Pharmaceuticals Inc., 2025. All rights reserved.
® © Aurinia Pharmaceuticals Inc., 2025. All rights reserved. Trademarks and logos are the property of Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals — Q3 2025 Earnings Presentation on 6ix